Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined With Monoclonal Antibody in Locally Advanced NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Surgical intervention remains the primary treatment option for early-stage lung cancer. With the proven efficacy of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC), neoadjuvant immunotherapy has increasingly become a focal point of research. Blocking vascular endothelial growth factor (VEGF) not only inhibits the proliferation of vascular endothelial cells and the formation of new blood vessels but also improves the tumor microenvironment and enhances the infiltration of cytotoxic T lymphocytes within it. Simultaneously targeting the VEGF and PD-L1 pathways can create a synergistic anti-cancer effect. PM8002 injection is a bispecific antibody drug that targets both PD-L1 and VEGF, functioning as a dual-action agent that combines immune suppression and anti-angiogenesis. In patients with locally advanced stage II-III NSCLC, neoadjuvant therapy that concurrently targets PD-L1/VEGF in combination with chemotherapy can improve pathological response rates, provided that the safety of the drug combination is maintained. This approach offers additional benefits to patients, prolongs event-free survival (EFS), and improves prognosis.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony nowotwór płuca stadium II lub III bez wcześniejszego leczenia antynowotworowego
- •Dobry ogólny stan zdrowia (wynik ECOG 0-1)
- •Spodziewana długość życia co najmniej 12 tygodni
- •Płuca mogą tolerować operację chirurgiczną
- •Brak przerzutów nowotworu do innych części ciała
- •Dobra funkcja wątroby, nerek i systemu krwiotwórczego
- •Kobiety i mężczyźni w wieku rozrodczym muszą używać skutecznej antykoncepcji przez 120 dni po leczeniu
✗ Disqualifies
- •Mutacja genu EGFR lub przekształcenie ALK w guzie
- •Obecność małokomórkowych składników raka płuca
- •Inne nowotwory złośliwe w ciągu ostatnich 5 lat
- •Wcześniejsze systemowe leczenie antynowotworowe raka płuca
- •Niestabilne choroby (aktywne infekcje, niekontrolowane wysokie ciśnienie, problemy z sercem, zawał w ostatnich 6 miesiącach)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
Shanghai Changzheng Hospital
Shanghai, China
Huadong Hospital Affiliated to Fudan University
Shanghai, China
Tongji Hospital of Tongji University
Shanghai, China
Shanghai Pulmonary Hospital
Shanghai, China
Shanghai General Hospital
Shanghai, China
Trial contact
Peng Zhang, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.